Microdosing semaglutide vs standard dosing

On the evidence, standard dosing wins. Microdosing semaglutide means taking less than the labeled doses, or spacing them further apart, an off-label practice with no agreed definition. A 2026 pharmacology commentary called high-quality evidence for it "essentially absent" (Expert Opinion on Pharmacotherapy, 2026).

Standard dosing follows the Wegovy label's 4-week steps. At the 2.4 mg maintenance dose, adults in STEP 1 lost an average of 14.9% of their body weight over 68 weeks, against 2.4% on placebo (Wegovy prescribing information). That trial used brand Wegovy, not a compounded product.

Here, low dose semaglutide means a dose held below the label's steps, the usual meaning of microdosing. The standard column follows the Wegovy label.

Scroll the table sideways to see both columns →

Semaglutide dosing comes down to how much you take each week and who decides when that changes, and on both the two approaches part ways.

What microdosing means

Semaglutide microdosing has no definition in any FDA label or completed trial. The 2026 commentary describes it as doses below the manufacturer's starting dose or longer gaps between doses, spread through patient communities and clinician anecdote. Reported methods include counting clicks on multidose pens, which the Ozempic instructions tell users not to do (Ozempic prescribing information).

Two people who say microdose can mean very different amounts, and since no label or trial supplies one, this article gives none.

How the standard dosing schedule works

The semaglutide dosing schedule in the Wegovy label starts at 0.25 mg once a week for 4 weeks, then moves through 0.5 mg, 1 mg and 1.7 mg at 4 weeks each. From week 17, adults take a maintenance dose of 1.7 mg or 2.4 mg, with 2.4 mg recommended. For people who have taken 2.4 mg for at least 4 weeks and need more weight reduction, the current label allows up to 7.2 mg a week.

That semaglutide titration has some room built in. In some cases the label lets a prescriber delay a dose increase by 4 weeks, and it lists 1.7 mg as a maintenance dose alongside 2.4 mg, so a slower climb or a lower ceiling can stay on label. Compounded semaglutide often comes in a multiple-dose vial, with the dose written in milligrams and units. For measuring it, see the guide to inject semaglutide at home.

What the evidence shows

Dose matters in the trials that tested it. In STEP 6, a 68-week trial in 401 East Asian adults, weekly semaglutide 1.7 mg lowered weight by an average of 9.6% and 2.4 mg by 13.2%, against 2.1% on placebo. In STEP UP, 7.2 mg lowered weight by 18.8%, against 15.5% on 2.4 mg and 3.9% on placebo over 72 weeks (Wegovy prescribing information). A dose-finding trial of daily injections pointed the same way: average loss was 6.0% on the smallest dose and 13.8% on the largest, against 2.3% on placebo (Lancet, 2018).

No trial has measured the doses people call microdoses. Closest is an electronic health record study of 814 people with at least three 0.25 mg starting-dose prescriptions over 6 months or more. In its matched analysis, their average weight loss at 12 months was 2.2% (Biology Methods and Protocols, 2026). It was observational, and its authors say it does not establish intentional microdosing. Registered microdosing studies, such as a small trial in adults with HIV, had posted no results on ClinicalTrials.gov as of November 3, 2026.

Every randomized trial above used brand semaglutide, not a compounded product. For the month-by-month picture, see realistic semaglutide results by month.

Who decides the dose

Either way, the dose is a prescription decision. MedlinePlus says not to use more or less semaglutide, or use it more often, than prescribed (MedlinePlus). FDA asks prescribers of compounded semaglutide to be vigilant in setting doses and titration schedules, and encourages patients to check with their prescriber or compounder how to measure each dose (FDA). A 2026 brief report for nurse practitioners counts microdosing among the unsupervised strategies people try when cost is a barrier (Journal of the American Association of Nurse Practitioners, 2026).

A full dose also creates a checkpoint. The NIDDK guide to obesity medicines says that if you have not lost at least 5% of your starting weight after 12 weeks on the full dose, your health care professional will probably advise you to stop. A dose held below the label's range never gets that check. Harbor's clinicians set the dose, and licensed clinicians are available 24/7.

Cost per month

Cost is one reason the 2026 commentary gives for microdosing, but whether a smaller dose saves money depends on how the drug is sold. Brand Wegovy pens deliver set doses, and in November 2025 the White House announced that Ozempic and Wegovy would cost $350 a month through TrumpRx (White House, 2025).

Harbor lists compounded semaglutide from $99 a month, and the price does not rise with the dose. Compounded semaglutide is not FDA approved, and FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. FDA declared the semaglutide shortage resolved in February 2025, and its April 2026 update reminds pharmacies that this kind of compounding must be for an individual patient with a prescription (FDA).

A microdose semaglutide plan has no label of its own, so the useful question is who should ask a clinician about a lower or slower dose. The Wegovy label already makes room for both, with a 4-week delay before a step in some cases and a 1.7 mg maintenance dose.

A conversation about dosing pace may suit you when:

• You want treatment that stays inside the label's dose range, with a clinician deciding each step
• You are weighing the 1.7 mg maintenance dose against 2.4 mg
• You are restarting after missing 2 or more weekly doses, when the Wegovy label says to restart escalation at a lower dose
• You want one monthly price that does not change with the dose

For a weekly semaglutide injection with clinician-set dosing, see Harbor semaglutide injection plans. A board-certified physician reviews your health history and decides whether treatment is appropriate, and if it is not the right fit, you are not charged.

Interest in "microdosing glp 1" rests on the hope that less drug can do the same job, and the labels and trials do not show that. In the trials above that compared weekly doses, the higher dose produced more average weight loss, and no completed trial has tested a microdose. When progress slows, a clinician's review and the label's next step are the tested path, as the semaglutide plateau explained lays out.

Standard, clinician-set dosing gives you defined steps, brand trial data behind them and a prescriber who can slow the climb when needed. That is the option to act on.